{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T20:59:36Z","timestamp":1776718776725,"version":"3.51.2"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["FT110100851"],"award-info":[{"award-number":["FT110100851"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1111\/jth.15209","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T11:46:23Z","timestamp":1607773583000},"page":"689-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-2557","authenticated-orcid":false,"given":"Xuejie","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da\u2010Yun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Paul Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrel W.","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4770-2910","authenticated-orcid":false,"given":"Yoshitomo","family":"Suhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3834-7398","authenticated-orcid":false,"given":"Craig M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8447-3408","authenticated-orcid":false,"given":"Jian\u2010Ke","family":"Tie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15209_bb0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.114.009107","article-title":"30\u2010year mortality after venous thromboembolism: a population\u2010based cohort study","volume":"130","author":"Sogaard","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/jth.15209_bb0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/jth.15209_bb0020","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.15209_bb0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrcardio.2013.73","article-title":"Oral anticoagulants in the management of venous thromboembolism","volume":"10","author":"Makaryus","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/jth.15209_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11239-016-1446-0","article-title":"Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"43","author":"Zirlik","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.15209_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.thromres.2011.04.011","article-title":"Vitamin K antagonists \u2010 current concepts and challenges","volume":"128","author":"Moualla","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15209_bb0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60 years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/jth.15209_bb0045","unstructured":"Warfarin \u2010 Drug Usage Statistics. ClinCalc; 2020; https:\/\/clincalc.com\/DrugStats\/Drugs\/Warfarin. Accessed June 30, 2020."},{"key":"10.1111\/jth.15209_bb0050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"10.1111\/jth.15209_bb0055","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"Li","year":"2004","journal-title":"Nature"},{"key":"10.1111\/jth.15209_bb0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/pgs-2017-0207","article-title":"Genotype\u2010guided warfarin therapy: current status","volume":"19","author":"Tavares","year":"2018","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jth.15209_bb0065","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose\u2010anticoagulant effect of warfarin","volume":"105","author":"D'Andrea","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0070","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2018-05-846592","article-title":"Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0075","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.100628","article-title":"Warfarin pharmacogenetics: a rising tide for its clinical value","volume":"125","author":"Johnson","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jth.15209_bb0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.558","article-title":"Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real\u2010world setting: a proposal for a new pharmacogenetic dosing approach","volume":"101","author":"Arwood","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.15209_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/pgs.15.48","article-title":"Development of a pharmacogenetic\u2010based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population\u2010specific calibration","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jth.15209_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2012.09150.x","article-title":"Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin international normalized ratio control and bleeding rates","volume":"158","author":"Lund","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15209_bb0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcm.2014.09.001","article-title":"Warfarin pharmacogenetics","volume":"25","author":"Johnson","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1111\/jth.15209_bb0100","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta\u2010analysis, and cost effectiveness analysis","volume":"359","author":"Lopez\u2010Lopez","year":"2017","journal-title":"BMJ"},{"key":"10.1111\/jth.15209_bb0105","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.clinthera.2017.05.358","article-title":"Effectiveness and safety of non\u2010vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta\u2010analyses","volume":"39","author":"Almutairi","year":"2017","journal-title":"Clin Ther"},{"key":"10.1111\/jth.15209_bb0110","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-019-57370-2","article-title":"Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta\u2010analysis","volume":"10","author":"Ng","year":"2020","journal-title":"Sci Rep"},{"key":"10.1111\/jth.15209_bb0115","doi-asserted-by":"crossref","first-page":"7636104","DOI":"10.1155\/2020\/7636104","article-title":"An update on the reversal of non\u2010vitamin K antagonist oral anticoagulants","volume":"2020","author":"Mujer","year":"2020","journal-title":"Adv Hematol"},{"key":"10.1111\/jth.15209_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-med-042617-092334","article-title":"Non\u2010vitamin K antagonist oral anticoagulants in the treatment of atrial fibrillation","volume":"70","author":"Fanaroff","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1111\/jth.15209_bb0125","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.14714","article-title":"Current challenges and future prospects in oral anticoagulant therapy","volume":"178","author":"Czuprynska","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15209_bb0130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","article-title":"Overview of the new oral anticoagulants: opportunities and challenges","volume":"35","author":"Yeh","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.15209_bb0135","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15209_bb0140","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/molecules25061465","article-title":"Antagonists of vitamin K\u2010popular coumarin drugs and new synthetic and natural coumarin derivatives","volume":"25","author":"Kasperkiewicz","year":"2020","journal-title":"Molecules"},{"key":"10.1111\/jth.15209_bb0145","first-page":"833","article-title":"Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry","volume":"111","author":"Le Heuzey","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15209_bb0150","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/jth.15209_bb0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1194\/jlr.R045559","article-title":"Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK\u20104 biosynthesis","volume":"55","author":"Shearer","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1111\/jth.15209_bb0160","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cmdc.201600009","article-title":"Redox polypharmacology as an emerging strategy to combat malarial parasites","volume":"11","author":"Sidorov","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1111\/jth.15209_bb0165","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1021\/acs.jmedchem.6b01717","article-title":"Synthesis of novel synthetic vitamin K analogues prepared by introduction of a heteroatom and a phenyl group that induce highly selective neuronal differentiation of neuronal progenitor cells","volume":"60","author":"Kimura","year":"2017","journal-title":"J Med Chem"},{"key":"10.1111\/jth.15209_bb0170","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.bmcl.2019.05.039","article-title":"Determining the necessity of phenyl ring pi\u2010character in warfarin","volume":"29","author":"Xing","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/jth.15209_bb0175","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/chem.201806277","article-title":"Cyclooctatetraene: a bioactive Cubane paradigm complement","volume":"25","author":"Xing","year":"2019","journal-title":"Chemistry"},{"key":"10.1111\/jth.15209_bb0180","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1039\/C9OB01238A","article-title":"The cubane paradigm in bioactive molecule discovery: further scope, limitations and the cyclooctatetraene complement","volume":"17","author":"Houston","year":"2019","journal-title":"Org Biomol Chem"},{"key":"10.1111\/jth.15209_bb0185","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/anie.201510675","article-title":"Validating Eaton's hypothesis: Cubane as a benzene bioisostere","volume":"55","author":"Chalmers","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1111\/jth.15209_bb0190","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2010-08-304303","article-title":"Functional study of the vitamin K cycle in mammalian cells","volume":"117","author":"Tie","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0195","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/jth.12306","article-title":"Evaluation of warfarin resistance using transcription activator\u2010like effector nucleases\u2010mediated vitamin K epoxide reductase knockout HEK293 cells","volume":"11","author":"Tie","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15209_bb0200","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2015-10-677633","article-title":"Characterization of vitamin K\u2010dependent carboxylase mutations that cause bleeding and nonbleeding disorders","volume":"127","author":"Tie","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0205","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood.2019004234","article-title":"A cell\u2010based high\u2010throughput screen identifies drugs that cause bleeding disorders by off\u2010targeting the vitamin K cycle","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0210","doi-asserted-by":"crossref","first-page":"31556","DOI":"10.1074\/jbc.M113.497297","article-title":"The Vitamin K Oxidoreductase Is a Multimer That Efficiently Reduces Vitamin K Epoxide to Hydroquinone to Allow Vitamin K\u2010dependent Protein Carboxylation","volume":"288","author":"Rishavy","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15209_bb0215","doi-asserted-by":"crossref","first-page":"14755","DOI":"10.1021\/bi0618518","article-title":"Identification of the N\u2010linked glycosylation sites of vitamin K\u2010dependent carboxylase and effect of glycosylation on carboxylase function","volume":"45","author":"Tie","year":"2006","journal-title":"Biochemistry"},{"key":"10.1111\/jth.15209_bb0220","first-page":"574","article-title":"Coumarin and indandione anticoagulants. Potentiators and antagonists","volume":"26","author":"Formiller","year":"1969","journal-title":"Am J Hosp Pharm"},{"key":"10.1111\/jth.15209_bb0225","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/jth.12019","article-title":"VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity","volume":"10","author":"Hodroge","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15209_bb0230","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/blood-2013-05-501692","article-title":"Human VKORC1 mutations cause variable degrees of 4\u2010hydroxycoumarin resistance and affect putative warfarin binding interfaces","volume":"122","author":"Czogalla","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.15209_bb0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bmcl.2016.11.073","article-title":"Synthesis of 2\u2010methyl\u20101,4\u2010naphthoquinones with higher gamma\u2010glutamyl carboxylase activity than MK\u20104 both in vitro and in vivo","volume":"27","author":"Vermeer","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/jth.15209_bb0240","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.3390\/ijms20123006","article-title":"New aspects of vitamin K research with synthetic ligands: transcriptional activity via SXR and neural differentiation activity","volume":"20","author":"Hirota","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1111\/jth.15209_bb0245","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4155\/fmc.13.70","article-title":"Vitamin K: a structural basis for the design of novel neuroprotective agents?","volume":"5","author":"Chou","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1111\/jth.15209_bb0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nsmb.3333","article-title":"Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer","volume":"24","author":"Shen","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"10.1111\/jth.15209_bb0255","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nsmb.3338","article-title":"Warfarin and vitamin K compete for binding to Phe55 in human VKOR","volume":"24","author":"Czogalla","year":"2017","journal-title":"Nat Struct Mol Biol"},{"key":"10.1111\/jth.15209_bb0260","doi-asserted-by":"crossref","first-page":"33071","DOI":"10.1074\/jbc.M113.477356","article-title":"Menadione (vitamin K3) is a catabolic product of oral phylloquinone (vitamin K1) in the intestine and a circulating precursor of tissue menaquinone\u20104 (vitamin K2) in rats","volume":"288","author":"Hirota","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15209_bb0265","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature09464","article-title":"Identification of UBIAD1 as a novel human menaquinone\u20104 biosynthetic enzyme","volume":"468","author":"Nakagawa","year":"2010","journal-title":"Nature"},{"key":"10.1111\/jth.15209_bb0270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev-nutr-082117-051741","article-title":"Key pathways and regulators of vitamin K function and intermediary metabolism","volume":"38","author":"Shearer","year":"2018","journal-title":"Annu Rev Nutr"},{"key":"10.1111\/jth.15209_bb0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0304-4165(90)90072-5","article-title":"Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K\u2010dependent carboxylase","volume":"1034","author":"Buitenhuis","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1111\/jth.15209_bb0280","first-page":"2610","article-title":"Nature of the vitamin K\u2010dependent CO2 fixation in microsomal membranes","volume":"37","author":"Houser","year":"1978","journal-title":"Fed Proc"},{"key":"10.1111\/jth.15209_bb0285","first-page":"621","article-title":"Effect of warfarin on the metabolism of phylloquinone (vitamin K1):dose\u2010response relationships in man","volume":"52","author":"Shearer","year":"1977","journal-title":"Clin Sci Mol Med"},{"key":"10.1111\/jth.15209_bb0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/237032a0","article-title":"Warfarin and the inhibition of vitamin K activity by an oxide metabolite","volume":"237","author":"Bell","year":"1972","journal-title":"Nature"},{"key":"10.1111\/jth.15209_bb0295","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13054-019-2492-8","article-title":"Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage","volume":"23","author":"Kuramatsu","year":"2019","journal-title":"Crit Care"},{"key":"10.1111\/jth.15209_bb0300","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1378\/chest.114.6.1546","article-title":"Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged","volume":"114","author":"Wentzien","year":"1998","journal-title":"Chest"},{"key":"10.1111\/jth.15209_bb0305","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta\u2010analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.15209_bb0310","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.thromres.2013.10.031","article-title":"Effectiveness of vitamin K in anticoagulation reversal for hip fracture surgery\u2013a prospective observational study","volume":"133","author":"Buecking","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15209_bb0315","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1172\/JCI112182","article-title":"Vitamin K\u2010dependent carboxylation and vitamin K metabolism in liver","volume":"76","author":"Wallin","year":"1985","journal-title":"Effects of warfarin. J Clin Invest"},{"key":"10.1111\/jth.15209_bb0320","first-page":"1","article-title":"Pharmacological aspects of vitamin K1. A clinical and experimental study in man","volume":"29","author":"Van der Meer","year":"1968","journal-title":"Thromb Diath Haemorrh Suppl"},{"key":"10.1111\/jth.15209_bb0325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0021-9258(18)51377-6","article-title":"Studies on the hemorrhagic sweet clover disease V. Identification and synthesis of the hemorrhagic agent","volume":"138","author":"Stahmann","year":"1941","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15209_bb0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.19.1.97","article-title":"The discovery of dicumarol and its sequels","volume":"19","author":"Link","year":"1959","journal-title":"Circulation"},{"key":"10.1111\/jth.15209_bb0335","doi-asserted-by":"crossref","first-page":"13544","DOI":"10.1038\/srep13544","article-title":"Coumarin derivatives from Ainsliaea fragrans and their anticoagulant activity","volume":"5","author":"Lei","year":"2015","journal-title":"Sci Rep\u2010Uk"},{"key":"10.1111\/jth.15209_bb0340","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF02178853","article-title":"The inhibition of the antidotal activity of vitamin K1 against coumarin anticoagulant drugs by its chloro analogue","volume":"16","author":"Lowenthal","year":"1960","journal-title":"Experientia"},{"key":"10.1111\/jth.15209_bb0345","first-page":"61","article-title":"Synthesis of menaquinone\u20102 derivatives as substrates for the liver microsomal vitamin K\u2010dependent carboxylase","volume":"1","author":"Cheung","year":"1988","journal-title":"BioFactors"},{"key":"10.1111\/jth.15209_bb0350","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1126\/science.180.4087.741","article-title":"Anticoagulant\u2010resistant rats: possible control by the use of the chloro analog of vitamin K 1","volume":"180","author":"Suttie","year":"1973","journal-title":"Science"},{"key":"10.1111\/jth.15209_bb0355","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2146\/ajhp150959","article-title":"Reversal agents for use with direct and indirect anticoagulants","volume":"73","author":"Smythe","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jth.15209_bb0360","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-5-21","article-title":"Hereditary combined deficiency of the vitamin K\u2010dependent clotting factors","volume":"5","author":"Napolitano","year":"2010","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622006924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622006924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/am-pdf\/10.1111\/jth.15209","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:31:06Z","timestamp":1761535866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622006924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1538783622006924"],"URL":"https:\/\/doi.org\/10.1111\/jth.15209","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel vitamin K derived anticoagulant tolerant to genetic variations of vitamin K epoxide reductase","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}